Intermittent Hypoxia Rewires the Liver Transcriptome and Fires up Fatty Acids Usage for Mitochondrial Respiration.

Nuclear Respiratory Factor (NRF) intermittent hypoxia (IH) liver mitochondria sleep apnea transcriptome

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2022
Historique:
received: 06 12 2021
accepted: 21 01 2022
entrez: 7 3 2022
pubmed: 8 3 2022
medline: 8 3 2022
Statut: epublish

Résumé

Sleep Apnea Syndrome (SAS) is one of the most common chronic diseases, affecting nearly one billion people worldwide. The repetitive occurrence of abnormal respiratory events generates cyclical desaturation-reoxygenation sequences known as intermittent hypoxia (IH). Among SAS metabolic sequelae, it has been established by experimental and clinical studies that SAS is an independent risk factor for the development and progression of non-alcoholic fatty liver disease (NAFLD). The principal goal of this study was to decrypt the molecular mechanisms at the onset of IH-mediated liver injury. To address this question, we used a unique mouse model of SAS exposed to IH, employed unbiased high-throughput transcriptomics and computed network analysis. This led us to examine hepatic mitochondrial ultrastructure and function using electron microscopy, high-resolution respirometry and flux analysis in isolated mitochondria. Transcriptomics and network analysis revealed that IH reprograms Nuclear Respiratory Factor- (NRF-) dependent gene expression and showed that mitochondria play a central role. We thus demonstrated that IH boosts the oxidative capacity from fatty acids of liver mitochondria. Lastly, the unbalance between oxidative stress and antioxidant defense is tied to an increase in hepatic ROS production and DNA damage during IH. We provide a comprehensive analysis of liver metabolism during IH and reveal the key role of the mitochondria at the origin of development of liver disease. These findings contribute to the understanding of the mechanisms underlying NAFLD development and progression during SAS and provide a rationale for novel therapeutic targets and biomarker discovery.

Identifiants

pubmed: 35252260
doi: 10.3389/fmed.2022.829979
pmc: PMC8894659
doi:

Types de publication

Journal Article

Langues

eng

Pagination

829979

Informations de copyright

Copyright © 2022 Gaucher, Vial, Montellier, Guellerin, Bouyon, Lemarie, Pelloux, Bertrand, Pernet-Gallay, Lamarche, Borel, Arnaud, Belaidi, Clément, Godin Ribuot, Aron-Wisnewsky and Pépin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Hepatol. 2016 Sep;65(3):470-2
pubmed: 27501737
Mitochondrion. 2012 Nov;12(6):607-16
pubmed: 23069012
Cell. 1999 Jul 9;98(1):115-24
pubmed: 10412986
Eur Respir J. 2017 Apr 19;49(4):
pubmed: 28424360
J Hepatol. 2012 Jan;56(1):225-33
pubmed: 21703181
Lancet Respir Med. 2019 Aug;7(8):687-698
pubmed: 31300334
Eur Respir Rev. 2019 Jun 26;28(152):
pubmed: 31243096
High Alt Med Biol. 2013 Sep;14(3):280-8
pubmed: 24028642
Chest. 2014 Mar 1;145(3):525-533
pubmed: 24264333
Nat Rev Dis Primers. 2015 Jun 25;1:15015
pubmed: 27188535
Am J Respir Crit Care Med. 2019 Apr 1;199(7):830-841
pubmed: 30422676
Pharmacol Ther. 2016 Dec;168:1-11
pubmed: 27492897
Metabolism. 2016 Aug;65(8):1124-35
pubmed: 27324067
Ann Hepatol. 2020 Sep - Oct;19(5):458-465
pubmed: 31959521
Diabetes. 2015 Jun;64(6):2254-64
pubmed: 25552598
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
Am J Respir Cell Mol Biol. 2021 Oct;65(4):390-402
pubmed: 34003729
FASEB J. 2020 Nov;34(11):14588-14601
pubmed: 32910512
Acta Physiol (Oxf). 2019 Jun;226(2):e13255
pubmed: 30635990
Cell. 2021 May 13;184(10):2537-2564
pubmed: 33989548
J Hepatol. 2011 Feb;54(2):348-56
pubmed: 21109325
Sci Rep. 2016 Apr 20;6:24618
pubmed: 27094951
Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25250-25259
pubmed: 31757851
Methods Mol Biol. 2018;1732:273-287
pubmed: 29480482
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
Sleep Med Rev. 2015 Apr;20:27-45
pubmed: 25155182
Antioxidants (Basel). 2021 Mar 09;10(3):
pubmed: 33803273
Antioxidants (Basel). 2020 Oct 13;9(10):
pubmed: 33066023
EMBO J. 2012 Oct 3;31(19):3809-20
pubmed: 22922464
Front Med (Lausanne). 2021 Feb 26;8:595371
pubmed: 33718398
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):578-588
pubmed: 33961787
Curr Opin Toxicol. 2016 Dec;1:80-91
pubmed: 28066829
Mitochondrion. 2021 Jul;59:113-122
pubmed: 33933661
Can J Cardiol. 2020 Jun;36(6):936-940
pubmed: 32387037
J Hepatol. 2021 Mar;74(3):638-648
pubmed: 33342543
Redox Biol. 2013 Jan 18;1:45-9
pubmed: 24024136
Front Pharmacol. 2019 Jan 08;9:1428
pubmed: 30670963
J Clin Invest. 2020 Oct 1;130(10):5536-5550
pubmed: 32925170
Biochim Biophys Acta. 2013 Aug;1830(8):4137-46
pubmed: 23597778
Lancet. 2021 Jun 5;397(10290):2212-2224
pubmed: 33894145
Sleep Med. 2021 Jan;77:357-364
pubmed: 32843301
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3172-3181
pubmed: 28595341

Auteurs

Jonathan Gaucher (J)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Guillaume Vial (G)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Emilie Montellier (E)

CNRS 5309, INSERM U1209, Institute for Advanced Biosciences, University Grenoble-Alpes, Grenoble, France.

Maëlle Guellerin (M)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Sophie Bouyon (S)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Emeline Lemarie (E)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Véronique Pelloux (V)

Nutrition and Obesities, Systemic Approaches, NutriOmics, Laboratory, Sorbonne University, Paris, France.
Nutrition Department, CRNH Ile de France, Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Paris, France.

Anne Bertrand (A)

INSERM U1216, Grenoble Institute of Neurosciences, University Grenoble-Alpes, Grenoble, France.

Karin Pernet-Gallay (K)

INSERM U1216, Grenoble Institute of Neurosciences, University Grenoble-Alpes, Grenoble, France.

Frederic Lamarche (F)

Laboratory of Fundamental and Applied Bioenergetics (LBFA), INSERM U1055, University Grenoble Alpes, Grenoble, France.

Anne-Laure Borel (AL)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Claire Arnaud (C)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Elise Belaidi (E)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Karine Clément (K)

Nutrition and Obesities, Systemic Approaches, NutriOmics, Laboratory, Sorbonne University, Paris, France.
Nutrition Department, CRNH Ile de France, Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Paris, France.

Diane Godin Ribuot (D)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Judith Aron-Wisnewsky (J)

Nutrition and Obesities, Systemic Approaches, NutriOmics, Laboratory, Sorbonne University, Paris, France.
Nutrition Department, CRNH Ile de France, Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Paris, France.

Jean-Louis Pépin (JL)

Hypoxia and PhysioPathology (HP2) Laboratory, INSERM U1300, CHU Grenoble-Alpes, University Grenoble-Alpes, Grenoble, France.

Classifications MeSH